<DOC>
	<DOCNO>NCT01035099</DOCNO>
	<brief_summary>The purpose study compare two different way administer Letrozole determine effectiveness block estrogen production ovarian stimulation patient breast cancer prior chemotherapy/radiotherapy oocytes embryos cryopreserved patient possibly achieve pregnancy treatment breast cancer . During standard ovulation stimulation , estrogen level exceed normal level may reach 10 time normal level 2 week period . This may desirable breast cancer patient . The study hop determine investigator stimulate oocyte development conventional way administer different dos Letrozole oocytes develop , keep estradiol level low , increase number oocyte investigator able recover , improve quality oocyte .</brief_summary>
	<brief_title>RCT Fixed v Titrated Letrozole Breast Cancer Patient Undergoing IVF</brief_title>
	<detailed_description>IVF process involve schedule injectable medication recruit several follicle , contain egg , retrieve ultrasound guidance fertilize . Embryos select transfer back patient 's uterus cryopreserved transfer later date . Letrozole potent highly selective third generation aromatase inhibitor develop early 1990 's . Aromatase enzyme cytochrome P-450 superfamily product CYP19 gene , catalyze reaction convert androgenic substance estrogens many tissue , include granulosa cell ovarian follicle . Letrozole competitively inhibit activity aromatase enzyme half-life approximately 48 hour . Because potent , sustain suppression plasma level estradiol , drug recently find superior tamoxifen treatment advanced-stage post-menopausal breast cancer . Conventional ovarian stimulation often result high estrogen level . Since high estrogen level often unsafe breast cancer patient , fix dose aromatase inhibitor protocol Letrozole develop , achieve effective ovarian stimulation reduce estrogen level prevent tumor progression short-term cancer recurrence . A fixed dose Letrozole use off-label ovulation induction agent many center stimulate egg development infertile couple patient prior undergo chemotherapy estrogen sensitive cancer . The purpose study determine titrate dose Letrozole comparison fix dose Letrozole gonadotropin stimulation IVF breast cancer patient result low estradiol level higher mature oocyte yield . In patient schedule undergo treatment IVF fertility preservation due breast cancer , would like prospectively randomize fix dose vs. titrate dose Letrozole . Due time restraint chemotherapy patient may present ovarian stimulation prior Day 2 menstrual cycle . If occur , Ganirelix may start suppress pituitary hormone regulation prior start stimulation medication day 2 menstrual bleeding . Eligible subject fully inform nature trial . Subjects could enrol IVF treatment point breast cancer diagnosis follow surgery initiation chemotherapy , chemotherapy prescribed oncologist . After obtain write informed consent , subject screen base inclusion/exclusion criterion , medical infertility history , Day 2/3 FSH estradiol , physical gynecological examination , oncology clearance Center 's standard screening evaluation IVF patient . A thorough gynecologic endocrinologic evaluation perform start treatment . Laboratory assessment include CBC , chemistry lipid profile ( see attach history physical form ) . Vital sign include blood pressure , pulse , weight assess baseline ( prior start stimulation medication ) , preoperative evaluation , day egg retrieval , post retrieval visit . Patients serum blood test bHCG , FSH , AMH , Estradiol , LH vaginal sonogram second day menstrual bleeding . Start stimulation medication proceed documentation serum negative pregnancy test . Patients eligible participate study one cycle vitro fertilization . Patients elect participate study provide gonadotropin medication . The start dose gonadotropin study group would determine patient ' age antral follicle count assess transvaginal ultrasound time initial consultation . See : Age &lt; 35 , Antral follicle Count &gt; 15 gonadotropin dose 225 IU ( 150 IU FSH + 75 IU HMG ; Age &lt; 35 , Antral follicle Count &lt; 15 gonadotropin dose 300 IU ( 150 IU FSH + 150 IU HMG ; Age 35-39 , Antral follicle Count &gt; 10 gonadotropin dose 300 IU ( 150 IU FSH + 150 IU HMG ; Age 35-39 , Antral follicle Count &lt; 10 gonadotropin dose 450 IU ( 225 IU FSH + 225 IU HMG ; Age &gt; 40 Independent antral follicle count , gonadotropin dose 450 IU ( 225 FSH + 225 IU HMG ) ; All patient would also give daily medication prevent ovulating ( Ganirelix ) , late cycle day # 7 continue HCG administration . Group # 1-Fixed Letrozole Group : Provided blood test sonograms within normal limit , patient randomize fix dose Letrozole start Letrozole 5mg daily ( orally ) second day menstrual cycle gonadotropin fourth day menstrual cycle ( Current Letrozole protocol CRMI ) . Patients monitor daily blood test estradiol LH sonogram every 1-3 day . Adjustments gonadotropin dose make per usual protocol IVF . Letrozole dose change continue two week egg retrieval . Group # 2-Titrated Letrozole Group : Provided blood test sonograms within normal limit , patient randomize titrate dose Letrozole , start gonadotropin even day # 2 menstrual cycle injectable follicle stimulate hormone ( FSH ) human menopausal gonadotropin ( HMG ) . Oral Letrozole add stimulation follow titrated regimen : Serum Estradiol level &lt; 150 pg/ml- No Letrozole ; Serum Estradiol Level 150-250 pg/ml- 2.5mg ; Serum Estradiol Level 251-350 pg/ml- 5 mg ; Serum Estradiol Level &gt; 350 pg/ml - 7.5 mg ; The maximal start dose Letrozole 5 mg , regardless initial estradiol level . The Letrozole dose may reduce appropriate suppression estradiol occur . The maximal increase decrease Letrozole dose 2.5 mg/ day . Patients monitor blood test estradiol LH sonogram start second day gonadotropin stimulation every 1-3 day monitor response adjust medication dose per usual IVF protocol . Letrozole stop group day HCG give resume egg retrieval . All patient stay dose Letrozole require last day ovarian stimulation 2 week stimulation keep estradiol level minimum . In addition , patient serum estradiol level draw weekly 2 week stimulation . Follow-up vital sign record along CBC , liver function panel , cholesterol panel 2 week stimulation . They also ask return 6 month 1 year completion chemotherapy AMH FSH level evaluate ovarian reserve , follow yearly basis phone/mail questionnaire person annual gynecological examination . All study patient provide emergency 24-hour phone number reach physician report adverse reaction medication , physician file adverse event report form principal investigator data safety monitor board . In addition , ask report adverse reaction medication follicular monitoring sonogram . All decision regard daily medication dos determine study principal investigator . Otherwise , treatment ovarian stimulation , egg retrieval , cryopreservation identical non-study patient undergo ovarian stimulation , oocyte retrieval , embryo/oocyte cryopreservation . Two week retrieval , follow-up instruction review . Patients advise refrain embryo transfer minimum 2 year chemotherapy . Patients permit undergo embryo transfer minimum one year complete chemotherapy clearance pregnancy obtain medical oncologist . Patients follow five year annual basis follow-up telephone call one investigator inquire health status ( see patient follow-up data sheet ) . A pregnancy registry create pregnancy occur follow enrollment study . Detailed pregnancy outcome collect age 2-5 year ( see baby follow-up data sheet attach ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Female breast cancer patient breast cancer diagnosis surgery undergo chemotherapy desire fertility preservation oocyte embryo cryopreservation Healthy subject accord documented medical history physical examination diagnose breast cancer ( estrogen progesterone receptor positive and/or negative ) Age le 45 year time inform consent Verbal write clearance medical surgical oncologist undergo control ovarian hyperstimulationIVF Delay chemotherapy treatment jeopardize cancer treatment outcome Ovarian stimulation affect cancer treatment plan Transvaginal ultrasound scan ( US ) within one month start stimulation clinically significant pelvic mass Serum FSH level ( Day 24 ) less 25 Negative pregnancy test prior begin Letrozole gonadotropin therapy Willing able comply protocol Voluntary provision write informed consent , prior study related procedure part normal medical care , understand subject withdraw consent time without prejudice future medical care Willingness provide followup information baby bear part study Patients medically clear oncologist Patients stage IV breast cancer base poor prognosis , general health patient , high uncertainty delay chemotherapy Any clinically relevant abnormal laboratory value ( FSH &gt; 25 miu/ml , renal function , ( great two time normal value ) , hepatic function ( great two time normal value ) , blood biochemistry , hematology ( elevate white blood count great 1.5 time normal value , hemoglobin &lt; 10mg/dL , thrombocytopenia ) , abnormal cholesterol profile ( total cholesterol â‰¥ 300mg/dL , abnormal LDL great 2 time normal value , ) base fast sample screen phase Contraindications use gonadotropin ( i.e . Tumors breast cancer , pregnancy , lactation , undiagnosed vaginal bleeding ) Recent current medical condition patient medically stable undergo stimulation egg retrieval , HIV infection , diabetes , cardiovascular disease , gastrointestinal , hepatic disease , undiagnosed pelvic mass , renal pulmonary disease History presence alcohol drug abuse within 12 month sign consent History severe allergic anaphylactic reaction hypersensitivity concomitant medication prescribe part treatment regimen protocol Administration investigational drug within three month prior sign inform consent Use insulin sensitize agent least one month prior sign informed consent Any patient candidate IVF</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Letrozole</keyword>
	<keyword>IVF ( vitro fertilization )</keyword>
	<keyword>Cryopreservation</keyword>
	<keyword>Fertility Preservation</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>